Prediabetes? Ain’t nobody got time for that!

Prediabetes? Ain’t nobody got time for that! The Ad Council’s type 2 prevention campaign misses the mark.

In the first of its kind campaign the ADA, AMA, and CDC released a series of Ad Council public service announcements aimed at preventing type 2 diabetes. The campaign is called So…Do I Have Prediabetes?

Boy did they miss the mark.

The campaign takes on a snarky tone. Now, I’ve been known to enjoy a snarky joke as much as the next person. But this snark is aimed at the patient, that just adds to the blame and shame people living with diabetes, especially type 2 diabetes, already face.

You eat bacon? Well, don’t. It’s a variation on the “Eat 100 candy bars and what do you get?” joke. We’ve all heard the punch line: Diabetes!

Only, it’s not true and it’s hateful. And when people feel blamed for their health or shamed for their behavior that disempowers them to change. Don’t believe that? Listen to what the research of Jane K. Dickinson, CDE has to say.

And what if you’re a busy mom?

Well, this busy mom doesn’t appreciate the sentiment. Yeah, busy-ness is a common excuse. I’ll cop to using it myself once or twice. Okay! I used it for about a million years while I was in pre-diabetes.

The doctor’s response to the patient saying she’s a busy mom made me think of this:

CharlieBrownLucyFootball

Lucy van Pelt pulling the football away at the last moment yet again and the ever trusting Charlie Brown taking a tumble mid-kick.

I don’t want my doctor to be paying a cruel joke on me. And I don’t want to end up the looser in this scenario.

But more damning is the image that comes to my mind when I reflect on what the busy mom says. Her distress is real. And yet her words come off more like this:

Ain't nobody got time for that!

And this is just plain wrong.

When one door closes…

MannKind and Sanofi announced the end of their Afrezza partnership. What happened?

News came last week that MannKind and Sanofi are ending their Afrezza partnership.

Afrezza, in case you don’t know, is a fast-acting insulin that is inhaled. Look ma, no needles! Instead of a needle poke you take several deep breaths. That has a certain appeal among the people getting poked.

There was some fanfare when Afrezza was approved by the FDA, and it even generated some Internet buzz. So what happened?

Sales were disappointing.

Afrezza had become the poster child for the complexities of introducing a new treatment to the market. It was proven effective. It received FDA approval. Doctors and patients were educated about its benefits and limitations; Afrezza can’t be used by people with asthma or lung ailments. But was Afrezza being stocked by pharmacies? And, more importantly, was it added to any of the payer formularies? Meaning, would any health insurance companies pay for it?

Success in pharma requires every step in the process of introducing a new treatment be successful. Afrezza was oh so close.

Meanwhile, every person using insulin continues to to poke themselves…daily…several times.


Update: On January 21, 2016 MannKind announced it has entered into a collaboration and license agreement with a newly formed entity, Receptor Life Sciences, Inc.

Today we ask Congress to hold a hearing on #‪diabetes‬

Please let your Representatives in Washington know how #diabetes affects us all. #hearingdiabetesvoices

Please let your Representatives in Washington know how #diabetes affects us all.

The American Diabetes Association says:

  • Nearly 30 million Americans living with diabetes and 86 million more at risk of developing it.
  • The total estimated cost of diagnosed diabetes in 2012 is $245 billion, including $176 billion in direct medical costs and $69 billion in reduced productivity.

And ask your Rep to help. How? Hold a hearing on #diabetes and address these questions:

The Cost of Testing

cc jessicafm

The New York Times ran an article last week on the high cost of diabetes—not for society, but for the individual.

Protecting Yourself From the Cost of Type 2 Diabetes [ http://www.nytimes.com/2010/11/13/health/13patient.html ]
By WALECIA KONRAD
Published: November 12, 2010
Diabetes patients spend $6,000 on average a year on care, one reason only 25 percent of diabetics get the treatment they need.

Oh wow. A useful article about the financial burden of diabetes. Then I read further…
The article asks what steps can patients take to reduce the cost of diabetes? Continue reading “The Cost of Testing”

An Election Day Plea

An Election Day Plee — Improve our nation’s food policies so that everyone’s health improves right now.

cc yaquina

As part of American Diabetes Month the ADA has put together a suggested list of blogging topics. Today’s suggested topic is:

Tuesday, November 2 Election Day – What issues are important to you? If you could tell your representatives one thing about diabetes, what would it be?  

The most obvious plea would be for funding research for a diabetes cure. But that’s like voting for Change We Can Believe In and expecting it to happen in 18 months. It’s a recipe for disappointment. What does a cure mean anyway? To me: No meds, no machines, no special routines. Will there be a cure? I hope so. Will I see it in my lifetime? I’m not so sure.

My immediate plea would be to improve this nation’s food policies and programs. This could have an enormous positive impact on people’s lives and health right now. And not just for the millions of people with diabetes, Continue reading “An Election Day Plea”